LOS ANGELES, June 12, 2017 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that Anthony J. Gringeri,
PhD, President and Chief Executive Officer of ImmunoCellular, will
present a corporate overview and business update at the Marcum
MicroCap Conference on Thursday, June 15,
2017 at 10:00 am ET at the
Grand Hyatt hotel, New York, New
York.
To access the live audio webcast of the Marcum presentation,
please log on through a link located in the Investors section of
ImmunoCellular's website at www.imuc.com,
under the Events & Presentations tab. A replay of
the webcast will be available one hour after the conclusion of the
live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The Company's lead product candidate, ICT-107, is a
patient-specific, dendritic cell-based immunotherapy targeting
glioblastoma and is currently being studied in an international
phase 3 trial. ImmunoCellular's pipeline also includes: ICT-121, a
patient-specific, dendritic cell-based immunotherapy targeting
CD133 found in recurrent glioblastoma; ICT-140, a patient-specific,
dendritic cell-based immunotherapy targeting ovarian cancer; and
the Stem-to-T-cell research program which engineers hematopoietic
stem cells to generate cytotoxic T cells. To learn more about
ImmunoCellular Therapeutics, please visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.652.4819
jane@jmgcomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-marcum-microcap-conference-on-june-15-2017-300472434.html
SOURCE ImmunoCellular Therapeutics, Ltd.